Expeditors International of Wshngtn Inc (EXPD) Stock Price Today
Aura AI Summary
Key Stats
- $24.47BMarket Cap
- -Volume
- IndustrialsSector
- $188.2752W High
- $113.1352W Low
- -Typical Hold Time
- $24.01BEnterprise Value
- 0.86%Div Yield
- -Trading Activity
Track Expeditors International of Wshngtn Inc (EXPD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Expeditors International of Wshngtn Inc has traded between a low of $113.13 and a high of $188.27, highlighting its annual price range. Buy and sell Expeditors International of Wshngtn Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Most Recent News
CoreWeave draws opposing bets from top investors Tepper and Soros amid AI cloud growth and debt concerns
In Q2 2026, David Tepper's Appaloosa fund initiated a significant new position in CoreWeave, an AI cloud infrastructure company, while George Soros's fund held puts against the same stock but reduced their bearish exposure during the quarter. CoreWea...
Nuclear stocks drop as AI revenue doubts and rising long-term rates hit valuations
Nuclear energy stocks like Oklo, Constellation Energy, and NuScale Power fell sharply due to concerns over AI-related capital expenditure and a spike in long-term Treasury yields to a 19-year high. AI companies reported lower-than-expected revenue fo...
Palvella advances QTORIN for skin disorders with positive Phase 3 data and $230M funding boost
Palvella is progressing its drug QTORIN, targeting microcystic lymphatic malformations and other skin diseases, supported by positive Phase 3 SELVA trial results. The company is leveraging a repeatable regulatory and commercial platform to expand QTO...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.